{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-304964","form_type":"8-K","ticker":"QTTB","cik":"0001661998","company_name":"Q32 Bio Inc.","filed_at":"2026-07-15T21:18:59+00:00","discovered_at":"2026-07-15T21:20:00.244065+00:00","generated_at":"2026-07-15T21:20:05.543890+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Q32 Bio prices $18.25/share offering of 6M shares and pre-funded warrants; net proceeds ~$187.6M","bullets":["Offering of 6,027,399 shares at $18.25 and pre-funded warrants for 4,931,506 shares at $18.2499.","Net proceeds estimated at $187.6M (or $215.8M if underwriters' option exercised in full).","Proceeds for working capital, research, clinical development, and commercialization of bempikibart.","Underwriters: Morgan Stanley, Jefferies, Cantor Fitzgerald, Oppenheimer; close expected July 16, 2026.","Pre-funded warrants exercisable at $0.0001/share, subject to ownership limits."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-304964","json":"https://secwatch.observer/filing/0001193125-26-304964.json","markdown":"https://secwatch.observer/filing/0001193125-26-304964.md","text":"https://secwatch.observer/filing/0001193125-26-304964.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661998/000119312526304964/0001193125-26-304964-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661998/000119312526304964/d150730d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-15T21:20:05.543890+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}